We need to follow the latest research and guidelines
These benefits have been demonstrated in large, well-designed cardiovascular outcome trials, including: Liraglutide (Victoza) the LEADER trial , which showed a significant reduction in cardiovascular death and all-cause mortality Semaglutide (Ozempic) the SUSTAIN-6 trial , demonstrating fewer major adverse cardiovascular events, particularly stroke Dulaglutide (Trulicity) the REWIND trial , which showed a significant reduction in major cardiovascular events even in people without established cardiovascular disease Tirzepatide (Mounjaro) cardiovascular outcome data from the SURPASS-CVOT programme are emerging, with early results suggesting cardiovascular benefit compared with insulin therapy These cardiovascular effects are a key reason why GLP-1based therapies are now recommended earlier in the treatment pathway for people with type 2 diabetes who have established heart disease or are at high cardiovascular risk

We also offer a 10 minute grace period for late arrivals before an appointment is considered a no-show
Ozempic: EPAR Public assessment report Kim SH, Kim SS, Kim HJ, Park EJ, Na DH
Novo Nordisk holds patents on semaglutide that extend through approximately 2032, preventing generic manufacturers from producing equivalent versions